Natural History Study of MNGIE

Suspended

• Conditions: Mitochondrial Neurogastrointestinal Encephalomyopathy
• Interventions: Other: Non-interventional

• Registration Number: NCT04245917
• Lead Sponsor: Entrada Therapeutics, Inc.

Brief Summary

Non-interventional, prospective, multicenter, natural history study of patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-01-27
• Study First Submitted QC: 2020-01-27
• Study First Posted: 2020-01-29
• Study Start: 2020-08-06
• Status Verified: 2021-07
• Last Update Submitted: 2021-07-16
• Last Update Posted: 2021-07-22
• Primary Completion: 2025-02
• Study Completion: 2026-02

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Has MNGIE

Read More

Exclusion Criteria

• Substance abuser

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
MNGIE Patients	Non-interventional	Patients with mitochondrial neurogastrointestinal encephalomyopathy

Primary Outcome Measures

Name	Time	Method
MNGIE Clinical Course	5 years	To evaluate the clinical course of MNGIE patients

Trial Locations

Locations (5)

Columbia University; 🇺🇸 New York, New York, United States

Baylor St Luke's Medical Center and Texas Children's Hospital at Baylor College of Medicine; 🇺🇸 Houston, Texas, United States

Children's Hospital Colorado; 🇺🇸 Aurora, Colorado, United States

Gazi Üniversitesi Tıp Fakültesi; 🇹🇷 Ankara, Turkey

Ege University Medical Faculty; Department of Pediatrics; 🇹🇷 Bornova, Izmir, Turkey